FULC
Fulcrum Therapeutics Inc

2,166
Mkt Cap
$481.65M
Volume
1.68M
52W High
$12.19
52W Low
$2.32
PE Ratio
-7.55
FULC Fundamentals
Price
$8.90
Prev Close
$8.76
Open
$8.69
50D MA
$9.32
Beta
1.63
Avg. Volume
794,822.63
EPS (Annual)
-$0.1569
P/B
2.43
Rev/Employee
$1.78M
Loading...
Loading...
News
all
press releases
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.7% - Here's What Happened
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.7% - What's Next...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat.com...
MarketBeat·6d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.6% - Here's What Happened
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.6% - Should You Sell...
MarketBeat·7d ago
News Placeholder
Robert Gould Sells 15,000 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) Director Robert Gould sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, November 19th. The shares were...
MarketBeat·14d ago
News Placeholder
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
Zacks·16d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Hits New 12-Month High - Should You Buy?
Fulcrum Therapeutics (NASDAQ:FULC) Hits New 12-Month High - Time to Buy...
MarketBeat·16d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 7.4% - Still a Buy?
Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 7.4% - Should You Buy...
MarketBeat·18d ago
News Placeholder
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ: FULC). Investors who...
Business Wire·1y ago
News Placeholder
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! FULC INVESTOR ALERT: Bronstein...
PR Newswire·1y ago
News Placeholder
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ: FULC). Investors who...
Business Wire·1y ago

Latest FULC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.